
Genetic Analysis Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Segment Data
Access more data
Revenue by
Geography
U.S.
Europe
RoW
Expenses by
Financials
Genetic Analysis AS's mission is to develop, document, clinically validate and commercialize in vitro diagnostic tests for diagnosis and characterizing of dysbiosis in Irritable Bowel Syndrome and Inflammatory Bowel Disease patients. Genetic Analysis AS will initially focus on new ways to help diagnose IBS-D. The company has developed a non-invasive laboratory test for microbiology that can help to confirm the presence of diarrheal IBS. The intent is to provide improved disease characterization for physicians treating large numbers of dysbiosis patients with IBS or IBD with the goal of helping the physician in the management of these patients.
Latest articles

Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023

Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023

Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
Ticker symbol
GEAN
Country
🇳🇴 Norway